Thermo Fisher Scientific Inc (TMO) Cash Flow Statement

A cash flow statement shows the actual cash a company generated and spent across operating, investing, and financing activities over a reporting period.

Thermo Fisher Scientific Inc. provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services internationally.

Total Cash From Operating Activities Chart for Thermo Fisher Scientific Inc

Thermo Fisher Scientific Inc (TMO) operating cash flow for FY2025 was USD 7.8B, a -9.8% change from FY2024. Thermo Fisher Scientific Inc's operating cash flow grew from USD 47.6M in 1989 to USD 7.8B in 2025 (16324.4% over 36 years). Operating cash flow compound annual growth rate: 5-year CAGR of -1.2%, 10-year CAGR of 10.7%, 20-year CAGR of 18.3%.

The most recent 3 years are real; the rest is blurred as a preview. Sign up free to unlock every line item, quarterly data, and the real full history. Free account: 8 years of history for 10 flagship companies. Premium: full history for 500+ companies. Premium is €10.00/month. See pricing.

Total Cash From Operating Activities (US Dollars)

R&D as % of Revenue

Compare with

Key Stats

Market Cap
$214.46B
Implied Share Price
$580.02
Enterprise Value
$247.30B
Revenue (TTM)
$46.34B
EBITDA
$11.74B
Profit Margin
15.04%
Trailing P/E
31.05
Forward P/E
22.47
Price/Book (MRQ)
3.96
Price/Sales (TTM)
4.63
EV/EBITDA
20.53
EV/Revenue
5.34
Dividend Yield
0.31%
Book Value
$139.75
Free Cash Flow (FY2025)
$6.29B
Free Cash Flow Yield
2.93%

Snapshot as of 7th August 2026 — not point-in-time controlled, may lag the live market by a few days.